Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus Clinical Trial

Official title:

A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Assess the Safety and Tolerability of Two Dose Levels of a New Formulation of Insulin Glargine and to Compare Its Pharmacodynamic and Pharmacokinetic Properties With 0.4 U/kg/Day Lantus® in an 8-days Multiple Dosing Regimen in Patients With Diabetes Mellitus Type 1

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01349855
• Other study ID #: TDR11626
• Secondary ID: 2010-023771-26
• Status: Completed
• Phase: Phase 1
• First received: April 15, 2011
• Last updated: May 31, 2011
• Start date: March 2011
• Est. completion date: May 2011

Study information

• Verified date: May 2011
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

To assess the safety and tolerability of two dose levels of a new insulin glargine formulation in a once-daily multiple dosing regimen

Secondary Objective:

To compare the pharmacokinetic and pharmacodynamic properties of two dose levels of a new insulin glargine formulation with 0.4 U/kg Lantus® in a once-daily multiple dosing regimen

Description:

The study duration per patient will be 33 to 68 days including 2 treatment periods of 10 days each separated by a wash-out period of 7-21 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria:

• Male or female subjects, between 18 and 65 years of age, inclusive, with diabetes mellitus type 1 for more than one year, as defined by the American Diabetes Association

• Body weight between 50.0 kg and 110.0 kg,

• Body Mass Index between 18.0 and 30.0 kg/m2 inclusive

• Stable insulin regimen for at least 2 months prior to study

• Certified as otherwise healthy for Type-1 Diabetes mellitus patient by assessment of medical history and physical examination

• Women of childbearing potential must have a negative pregnancy test and must use a highly effective method of birth control. During the entire study female subjects of child bearing potential must use two independent methods of contraception. The accepted double contraception methods include use of an intra-uterine device or hormonal contraception in addition to one of the following contraceptive options: 1) condom; 2) diaphragm; cervical/vault cap; 3) spermicide.

Exclusion criteria:

• Any history or presence of clinically relevant cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic (apart from diabetes mellitus type 1), hematological, neurological, psychiatric, systemic (affecting the body as a whole), ocular, gynecologic (if female), or infectious disease; any acute infectious disease or signs of acute illness

• More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months

• Presence or history of a drug allergy or clinically significant allergic disease according to the Investigator's judgment

• Participation in a trial with any investigational drug during the past three months

• Symptoms of a clinically significant illness in the 3 months before the study, which, according to the investigator's opinion, could interfere with the purposes of the study

• Regular use of any medication other than insulins in the last month before study start with the exception of thyroid hormones, lipid-lowering and antihypertensive drugs, and, if female, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days

• Known hypersensitivity to insulin glargine or excipients of the study drug

• Any history or presence of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in first degree relatives (parents, siblings or children)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Drug:
• Insulin glargine HOE901
Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous

Locations

Country	Name	City	State
Germany	Investigational site number 276001	Neuss

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety in terms of adverse and serious adverse events, vital signs, ECG, safety laboratory		up to day 10 of each period	Yes
Secondary	Glucose infusion rate		up to day 10 of each period	No
Secondary	Pharmacokinetic parameter : Cmax		up to day 10 of each period	No
Secondary	Pharmacokinetic parameter : Tmax		up to day 10 of each period	No
Secondary	Pharmacokinetic parameter : AUC		up to day 10 of each period	No